Current treatment strategies for targeting virulence factors and biofilm formation in Acinetobacter baumannii

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. (IDSA) IDS of A. Combating antimicrobial resistance: policy recommendations to save lives. Clin. Infect. Dis. 2011;52:S397–S428.
  MedlineGoogle Scholar
• 2. Scholtz V, Vaňková E, Kašparová P et al. Non-thermal plasma treatment of ESKAPE pathogens: a review. Front. Microbiol. 2021;12:737635.
  MedlineGoogle Scholar
• 3. Karlowsky JA, Hoban DJ, Hackel MA et al. Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia–Pacific countries: SMART 2013–2015. J. Med. Microbiol. 2017;66:61–69.
  MedlineGoogle Scholar
• 4. Santajit S, Indrawattana N. Mechanisms of antimicrobial resistance in ESKAPE pathogens. Biomed. Res. Int. 2016;2016:2475067.
  MedlineGoogle Scholar
• 5. Llaca-Díaz JM, Mendoza-Olazarán S, Camacho-Ortiz A et al. One-year surveillance of ESKAPE pathogens in an intensive care unit of Monterrey, Mexico. Chemotherapy 2013;58:475–481.
  Google Scholar
• 6. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care setting. Am. J. Infect. Control 2008;36:309–332.
  MedlineGoogle Scholar
• 7. Dudeck MA, Weiner LM, Allen-Bridson K et al. National Healthcare Safety Network (NHSN) report, data summary for 2012, device-associated module. Am. J. Infect. Control. 2013;41:1148–1166.
  MedlineGoogle Scholar
• 8. Rello J, Sonora R, Jubert P et al. Pneumonia in intubated patients: role of respiratory airway care. Am. J. Respir. Crit. Care Med. 1996;154:111–115.
  Medline CASGoogle Scholar
• 9. Choi JY, Kwak YG, Yoo H et al. Trends in the distribution and antimicrobial susceptibility of causative pathogens of device-associated infection in Korean intensive care units from 2006 to 2013: results from the Korean Nosocomial Infections Surveillance System (KONIS). J. Hosp. Infect. 2016;92:363–371.
  Medline CASGoogle Scholar
• 10. Icmr. Annual Report 2021: Antimicrobial Resistance Research and Surveillance Network. 2021. https://main.icmr.nic.in/sites/default/files/upload_documents/AMR_Annual_Report_2021.pdf
  Google Scholar
• 11. Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect. Dis. 2008;8:751–762.
  MedlineGoogle Scholar
• 12. Rangel K, Chagas TPG, De-Simone SG. Acinetobacter baumannii infections in times of COVID-19 pandemic. Pathogens 2021;10:1006.
  Medline CASGoogle Scholar
• 13. Li J, Wang J, Yang Y et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. Antimicrob. Resist. Infect. Control 2020;9:1–7.
  MedlineGoogle Scholar
• 14. Sathyakamala R, Peace AR, Shanmugam P. A comparative study on bacterial co-infections and prevalence of multidrug resistant organisms among patients in COVID and non-COVID intensive care units. J. Prev. Med. Hyg. 2022;63:E19.
  MedlineGoogle Scholar
• 15. Hafiz TA, Alghamdi SS, Mubaraki MA et al. A two-year retrospective study of multidrug-resistant Acinetobacter baumannii respiratory infections in critically Ill patients: clinical and microbiological findings. J. Infect. Public Health 2023;16:313–319.
  MedlineGoogle Scholar
• 16. Jamal M, Ahmad W, Andleeb S et al. Bacterial biofilm and associated infections. J. Chinese Med. Assoc. 2018;81:7–11.
  MedlineGoogle Scholar
• 17. Olson PD, Hunstad DA. Subversion of host innate immunity by uropathogenic Escherichia coli. Pathogens 2016;5:2.
  MedlineGoogle Scholar
• 18. Donlan RM. Biofilms: microbial life on surfaces. Emerg. Infect. Dis. 2002;8:881.
  MedlineGoogle Scholar
• 19. Kovács ÁT, van Gestel J, Kuipers OP. The protective layer of biofilm: a repellent function for a new class of amphiphilic proteins. Mol. Microbiol. 2012;85:8–11.
  Medline CASGoogle Scholar
• 20. Uruén C, Chopo-Escuin G, Tommassen J et al. Biofilms as promoters of bacterial antibiotic resistance and tolerance. Antibiotics 2020;10:3.
  Google Scholar
• 21. Gedefie A, Demsis W, Ashagrie M et al. Acinetobacter baumannii biofilm formation and its role in disease pathogenesis: a review. Infect Drug Resist. 2021;3711–3719.
  MedlineGoogle Scholar
• 22. Rello J, Sonora R, Jubert P et al. Pneumonia in intubated patients: role of respiratory airway care. Am. J. Respir. Crit. Care Med. 1996;154:111–115.
  Medline CASGoogle Scholar
• 23. Jackson-Litteken CD, Di Venanzio G, Le N-H et al. InvL, an invasin-like adhesin, is a type II secretion system substrate required for Acinetobacter baumannii uropathogenesis. mBio. 2022;13(3):e00258–22.
  MedlineGoogle Scholar
• 24. Abdi-Ali A, Hendiani S, Mohammadi P et al. Assessment of biofilm formation and resistance to imipenem and ciprofloxacin among clinical isolates of Acinetobacter baumannii in Tehran. Jundishapur J. Microbiol. 2014;7(1):e8606.
  MedlineGoogle Scholar
• 25. Choe H, Tatro JM, Hausman BS et al. Staphylococcus aureus and Acinetobacter baumannii inhibit osseointegration of orthopedic implants. Infect. Immun. 2022;90:e00669–21.
  Medline CASGoogle Scholar
• 26. Di Venanzio G, Flores-Mireles AL, Calix JJ et al. Urinary tract colonization is enhanced by a plasmid that regulates uropathogenic Acinetobacter baumannii chromosomal genes. Nat. Commun. 2019;10:1–13.
  Medline CASGoogle Scholar
• 27. Upmanyu K, Haq QMR, Singh R. Factors mediating Acinetobacter baumannii biofilm formation: opportunities for developing therapeutics. Curr. Res. Microb. Sci. 2022;3:100131.
  Medline CASGoogle Scholar
• 28. Bales PM, Renke EM, May SL et al. Purification and characterization of biofilm-associated EPS exopolysaccharides from ESKAPE organisms and other pathogens. PLOS ONE 2013;8:e67950.
  Medline CASGoogle Scholar
• 29. Sahu PK, Iyer PS, Barage SH et al. Characterization of the algC gene expression pattern in the multidrug resistant Acinetobacter baumannii AIIMS 7 and correlation with biofilm development on abiotic surface. Scient. World J. 2014;2014:593546.
  Google Scholar
• 30. Jin JS, Kwon S-O, Moon DC et al. Acinetobacter baumannii secretes cytotoxic outer membrane protein A via outer membrane vesicles. PLOS ONE 2011;6:e17027.
  Medline CASGoogle Scholar
• 31. Beveridge TJ. Structures of Gram-negative cell walls and their derived membrane vesicles. J. Bacteriol. 1999;181:4725–4733.
  Medline CASGoogle Scholar
• 32. Lee JS, Lee JC, Lee C-M et al. Outer membrane protein A of Acinetobacter baumannii induces differentiation of CD4+ T cells toward a Th1 polarizing phenotype through the activation of dendritic cells. Biochem. Pharmacol. 2007;74:86–97.
  Medline CASGoogle Scholar
• 33. López-Leal G, Zuniga-Moya JC, Castro-Jaimes S et al. Unexplored genetic diversity of multidrug-and extremely drug-resistant Acinetobacter baumannii isolates from tertiary hospitals in Honduras. Microb. Drug Resist. 2019;25:690–695.
  Medline CASGoogle Scholar
• 34. Tsai Y-K, Liou C-H, Lin J-C et al. Effects of different resistance mechanisms on antimicrobial resistance in Acinetobacter baumannii: a strategic system for screening and activity testing of new antibiotics. Int. J. Antimicrob. Agents 2020;55:105918. • This work explains the resistance mechanism of 50 genetically engineered A. baumannii strains. This study also evaluates the compounds that specified antimicrobial resistance.
  Medline CASGoogle Scholar
• 35. Ries JI, Heß M, Nouri N et al. CipA mediates complement resistance of Acinetobacter baumannii by formation of a factor I-dependent quadripartite assemblage. Front. Immunol. 2022;13:942482. • Reports the novel Factor I-dependent mechanisms of complement inactivation mediated by CipA of A. baumannii.
  Medline CASGoogle Scholar
• 36. Groisman EA. Feedback control of two-component regulatory systems. Annu. Rev. Microbiol. 2016;70:103–124.
  Medline CASGoogle Scholar
• 37. Kim SY, Kim MH, Kim S Il et al. The sensor kinase BfmS controls production of outer membrane vesicles in Acinetobacter baumannii. BMC Microbiol. 2019;19:1–13.
  MedlineGoogle Scholar
• 38. Kim H-J, Kim N-Y, Ko S-Y et al. Complementary regulation of BfmRS two-component and AbaIR quorum sensing systems to express virulence-associated genes in Acinetobacter baumannii. Int. J. Mol. Sci. 2022;23:13136.
  Medline CASGoogle Scholar
• 39. Cerqueira GM, Kostoulias X, Khoo C et al. A global virulence regulator in Acinetobacter baumannii and its control of the phenylacetic acid catabolic pathway. J. Infect. Dis. 2014;210:46–55.
  Medline CASGoogle Scholar
• 40. Liou M-L, Soo P-C, Ling S-R et al. The sensor kinase BfmS mediates virulence in Acinetobacter baumannii. J. Microbiol. Immunol. Infect. 2014;47:275–281.
  Medline CASGoogle Scholar
• 41. Tomaras AP, Dorsey CW, Edelmann RE et al. Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii: involvement of a novel chaperone-usher pili assembly system. Microbiology (N Y) 2003;149:3473–3484.
  Medline CASGoogle Scholar
• 42. Loehfelm TW, Luke NR, Campagnari AA. Identification and characterization of an Acinetobacter baumannii biofilm-associated protein. J. Bacteriol. 2008;190:1036–1044.
  Medline CASGoogle Scholar
• 43. Gaddy JA, Tomaras AP, Actis LA. The Acinetobacter baumannii 19606 OmpA protein plays a role in biofilm formation on abiotic surfaces and in the interaction of this pathogen with eukaryotic cells. Infect. Immun. 2009;77:3150–3160.
  Medline CASGoogle Scholar
• 44. Choi CH, Lee JS, Lee YC et al. Acinetobacter baumannii invades epithelial cells and outer membrane protein A mediates interactions with epithelial cells. BMC Microbiol. 2008;8:1–11.
  MedlineGoogle Scholar
• 45. Choi AHK, Slamti L, Avci FY et al. The pgaABCD locus of Acinetobacter baumannii encodes the production of poly-β-1-6-N-acetylglucosamine, which is critical for biofilm formation. J. Bacteriol. 2009;191:5953–5963.
  Medline CASGoogle Scholar
• 46. Bi Y, Hubbard C, Purushotham P et al. Insights into the structure and function of membrane-integrated processive glycosyltransferases. Curr. Opin. Struct. Biol. 2015;34:78–86.
  Medline CASGoogle Scholar
• 47. Flannery A, Le Berre M, Pier GB et al. Glycomics microarrays reveal differential in situ presentation of the biofilm polysaccharide poly-N-acetylglucosamine on Acinetobacter baumannii and Staphylococcus aureus cell surfaces. Int. J. Mol. Sci. 2020;21:2465.
  Medline CASGoogle Scholar
• 48. Geisinger E, Isberg RR. Antibiotic modulation of capsular exopolysaccharide and virulence in Acinetobacter baumannii. PLoS Pathog. 2015;11:e1004691.
  MedlineGoogle Scholar
• 49. Cirioni O, Silvestri C, Ghiselli R et al. Therapeutic efficacy of buforin II and rifampin in a rat model of Acinetobacter baumannii sepsis. Crit. Care Med. 2009;37:1403–1407.
  Medline CASGoogle Scholar
• 50. Jiang Z, Vasil AI, Gera L et al. Rational design of α-helical antimicrobial peptides to target Gram-negative pathogens, Acinetobacter baumannii and Pseudomonas aeruginosa: utilization of charge, ‘specificity determinants,’ total hydrophobicity, hydrophobe type and location as design parameters to improve the therapeutic ratio. Chem. Biol. Drug Des. 2011;77:225–240.
  MedlineGoogle Scholar
• 51. Wortham BW, Oliveira MA, Patel CN. Polyamines in bacteria: pleiotropic effects yet specific mechanisms. Genus Yersinia: From Genom. Funct. 2007;106–115.
  Google Scholar
• 52. Barbagallo M, Di Martino ML, Marcocci L et al. A new piece of the Shigella pathogenicity puzzle: spermidine accumulationby silencing of the speG gene. PLOS ONE 2011;6:e27226.
  Medline CASGoogle Scholar
• 53. Fang S-B, Huang C-J, Huang C-H et al. speG is required for intracellular replication of Salmonella in various human cells and affects its polyamine metabolism and global transcriptomes. Front. Microbiol. 2017;8:2245.
  MedlineGoogle Scholar
• 54. Armalytė J, Čepauskas A, Šakalytė G et al. A polyamine acetyltransferase regulates the motility and biofilm formation of Acinetobacter baumannii. Nat. Commun. 2023;14:3531. • The findings of this work shows that A. baumannii encodes a novel acetyltransferase, Dpa, that acetylates 1,3-diaminopropane, directly affecting the bacterium motility and influencing the biofilm formation and adhesion on biotic and abiotic surfaces.
  Medline CASGoogle Scholar
• 55. Stickler DJ. Bacterial biofilms in patients with indwelling urinary catheters. Nat. Clin. Pract. Urol. 2008;5:598–608.
  Medline CASGoogle Scholar
• 56. Høiby N, Bjarnsholt T, Givskov M et al. Antibiotic resistance of bacterial biofilms. Int. J. Antimicrob Agents 2010;35:322–332.
  MedlineGoogle Scholar
• 57. Greene C, Wu J, Rickard AH et al. Evaluation of the ability of Acinetobacter baumannii to form biofilms on six different biomedical relevant surfaces. Lett. Appl. Microbiol. 2016;63:233–239.
  Medline CASGoogle Scholar
• 58. El-Shazly S, Dashti A, Vali L et al. Molecular epidemiology and characterization of multiple drug-resistant (MDR) clinical isolates of Acinetobacter baumannii. Int. J. Infect. Dis. 2015;41:42–49.
  Medline CASGoogle Scholar
• 59. Sechi LA, Karadenizli A, Deriu A et al. PER-1 type beta-lactamase production in Acinetobacter baumannii is related to cell adhesion. Med. Sci. Monit. 2004;10:BR180–184.
  Medline CASGoogle Scholar
• 60. Yang C-H, Su P-W, Moi S-H et al. Biofilm formation in Acinetobacter Baumannii: genotype-phenotype correlation. Molecules 2019;24:1849.
  Medline CASGoogle Scholar
• 61. Skerniškytė J, Karazijaitė E, Deschamps J et al. Blp1 protein shows virulence-associated features and elicits protective immunity to Acinetobacter baumannii infection. BMC Microbiol. 2019;19:1–12.
  MedlineGoogle Scholar
• 62. Lee H-W, Koh YM, Kim J et al. Capacity of multidrug-resistant clinical isolates of Acinetobacter baumannii to form biofilm and adhere to epithelial cell surfaces. Clin. Microbiol. Infect. 2008;14:49–54.
  Medline CASGoogle Scholar
• 63. Rao RS, Karthika RU, Singh SP et al. Correlation between biofilm production and multiple drug resistance in imipenem resistant clinical isolates of Acinetobacter baumannii. Indian J. Med. Microbiol. 2008;26:333–337.
  MedlineGoogle Scholar
• 64. Bhargava N, Singh SP, Sharma A et al. Attenuation of quorum sensing-mediated virulence of Acinetobacter baumannii by Glycyrrhiza glabra flavonoids. Future Microbiol. 2015;10:1953–1968.
  CASGoogle Scholar
• 65. Subhadra B, Oh MH, Choi CH. Quorum sensing in Acinetobacter: with special emphasis on antibiotic resistance, biofilm formation and quorum quenching. AIMS Microbiol. 2016;2:27–41.
  CASGoogle Scholar
• 66. Sun X, Ni Z, Tang J et al. The abaI/abaR quorum sensing system effects on pathogenicity in Acinetobacter baumannii. Front. Microbiol. 2021;12:679241.
  MedlineGoogle Scholar
• 67. Moon KH, Weber BS, Feldman MF. Subinhibitory concentrations of trimethoprim and sulfamethoxazole prevent biofilm formation by Acinetobacter baumannii through inhibition of Csu pilus expression. Antimicrob. Agents Chemother. 2017;61:10–1128.
  Google Scholar
• 68. Subhadra B, Surendran S, Lim BR et al. Complete genome sequence and phylogenetic analysis of nosocomial pathogen Acinetobacter nosocomialis strain NCTC 8102. Genes Genom. 2019;41:1063–1075.
  Medline CASGoogle Scholar
• 69. Guo HN, Xiang J. Influences of abaR gene on biofilm formation of Acinetobacter baumannii. Zhonghua Shao Shang Za Zhi. 2017;33:200–205.
  Medline CASGoogle Scholar
• 70. López-Martín M, Dubern J-F, Alexander MR et al. Abam regulates quorum sensing, biofilm formation, and virulence in Acinetobacter baumannii. J. Bacteriol. 2021;203:10–1128.
  Google Scholar
• 71. Anbazhagan D, Mansor M, Yan GOS et al. Detection of quorum sensing signal molecules and identification of an autoinducer synthase gene among biofilm forming clinical isolates of Acinetobacter spp. PLOS ONE 2012;7:e36696.
  Medline CASGoogle Scholar
• 72. Fiester SE, Actis LA. Stress responses in the opportunistic pathogen Acinetobacter baumannii. Future Microbiol. 2013;8:353–365.
  CASGoogle Scholar
• 73. Sheldon JR, Skaar EP. Acinetobacter baumannii can use multiple siderophores for iron acquisition, but only acinetobactin is required for virulence. PLoS Pathog. 2020;16:e1008995.
  Medline CASGoogle Scholar
• 74. Gaddy JA, Arivett BA, McConnell MJ et al. Role of acinetobactin-mediated iron acquisition functions in the interaction of Acinetobacter baumannii strain ATCC 19606T with human lung epithelial cells, Galleria mellonella caterpillars, and mice. Infect. Immun. 2012;80:1015–1024.
  Medline CASGoogle Scholar
• 75. Hatefi Oskuei R, Darvish Alipour Astaneh S, Rasooli I. A conserved region of Acinetobacter trimeric autotransporter adhesion, Ata, provokes suppression of Acinetobacter baumannii virulence. Arch. Microbiol. 2021;203:3483–3493.
  MedlineGoogle Scholar
• 76. Tomaras AP, Flagler MJ, Dorsey CW et al. Characterization of a two-component regulatory system from Acinetobacter baumannii that controls biofilm formation and cellular morphology. Microbiology (NY) 2008;154:3398–3409.
  Medline CASGoogle Scholar
• 77. He X, Lu F, Yuan F et al. Biofilm formation caused by clinical Acinetobacter baumannii isolates is associated with overexpression of the AdeFGH efflux pump. Antimicrob. Agents Chemother. 2015;59:4817–4825.
  Medline CASGoogle Scholar
• 78. De Gregorio E, Del Franco M, Martinucci M et al. Biofilm-associated proteins: news from Acinetobacter. BMC Genom. 2015;16:1–14.
  MedlineGoogle Scholar
• 79. Ramezanalizadeh F, Owlia P, Rasooli I. Type I pili, CsuA/B and FimA induce a protective immune response against Acinetobacter baumannii. Vaccine 2020;38:5436–5446.
  Medline CASGoogle Scholar
• 80. Giardina BJ, Shahzad S, Huang W et al. Heme uptake and utilization by hypervirulent Acinetobacter baumannii LAC-4 is dependent on a canonical heme oxygenase (abHemO). Arch. Biochem. Biophys. 2019;672:108066.
  Medline CASGoogle Scholar
• 81. Camarena L, Bruno V, Euskirchen G et al. Molecular mechanisms of ethanol-induced pathogenesis revealed by RNA-sequencing. PLoS Pathog. 2010;6:e1000834.
  MedlineGoogle Scholar
• 82. Jacobs AC, Hood I, Boyd KL et al. Inactivation of phospholipase D diminishes Acinetobacter baumannii pathogenesis. Infect. Immun. 2010;78:1952–1962.
  Medline CASGoogle Scholar
• 83. Das T, Paino D, Manoharan A et al. Conditions under which glutathione disrupts the biofilms and improves antibiotic efficacy of both ESKAPE and non-ESKAPE species. Front. Microbiol. 2019;10:2000.
  MedlineGoogle Scholar
• 84. Mayer C, Muras A, Parga A et al. Quorum sensing as a target for controlling surface associated motility and biofilm formation in Acinetobacter baumannii ATCC^® 17978TM. Front. Microbiol. 2020;11:565548.
  MedlineGoogle Scholar
• 85. Chow JY, Yang Y, Tay SB et al. Disruption of biofilm formation by the human pathogen Acinetobacter baumannii using engineered quorum-quenching lactonases. Antimicrob. Agents Chemother. 2014;58:1802–1805.
  MedlineGoogle Scholar
• 86. Gawande PV, Leung KP, Madhyastha S. Antibiofilm and antimicrobial efficacy of DispersinB^®-KSL-W peptide-based wound gel against chronic wound infection associated bacteria. Curr. Microbiol. 2014;68:635–641.
  Medline CASGoogle Scholar
• 87. Lood R, Winer BY, Pelzek AJ et al. Novel phage lysin capable of killing the multidrug-resistant Gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model. Antimicrob. Agents Chemother. 2015;59:1983–1991.
  Medline CASGoogle Scholar
• 88. Ouslimani S, Bendahou M, Abedelmounaim K et al. Antibacterial and anti-biofilm efficiency of twenty Algerian plants essential oils against resistant Acinetobacter baumannii. J. Essent. Oil Bear. Plants 2023;26:206–231. •• Reported the antibacterial and antibiofilm properties of 20 essential oil derived from Algerian plants against MDR and XDR A. baumannii.
  CASGoogle Scholar
• 89. Slobodníková L, Fialová S, Rendeková K et al. Antibiofilm activity of plant polyphenols. Molecules. 2016;21:1717.
  MedlineGoogle Scholar
• 90. Bodet C, Grenier D, Chandad F et al. Potential oral health benefits of cranberry. Crit. Rev. Food Sci. Nutr. 2008;48:672–680.
  Medline CASGoogle Scholar
• 91. Raorane CJ, Lee J-H, Kim Y-G et al. Antibiofilm and antivirulence efficacies of flavonoids and curcumin against Acinetobacter baumannii. Front. Microbiol. 2019;10:990.
  MedlineGoogle Scholar
• 92. Valizadeh M, Beigomi M, Fazeli-Nasab B. Antibacterial and Anti biofilm effects of ethanol and aceton leaf extract of Momordica charantia and Tecomella undulata against Acinetobacter baumannii. Int. J. Adv. Biol. Biomed. Res. 2020;8:403–418.
  CASGoogle Scholar
• 93. Meccatti VM, Martins KMC, Ramos L de P et al. Synergistic antibiofilm action of cinnamomum verum and Brazilian green propolis hydroethanolic extracts against multidrug-resistant strains of Acinetobacter baumannii and Pseudomonas aeruginosa and their biocompatibility on human keratinocytes. Molecules 2023;28:6904.
  Medline CASGoogle Scholar
• 94. Wenjun W. Antibacterial effect of chitosan-modified Fe3O4 nanozymes on Acinetobacter baumannii. J. Microbiol. Biotechnol. 2022;32:263. •• This is the first in vitro study demonstrating that chitosan-modified Fe3O4 potentially inhibits the growth of drug-resistant A. baumannii.
  MedlineGoogle Scholar
• 95. Chen CH, Lu TK. Development and challenges of antimicrobial peptides for therapeutic applications. Antibiotics 2020;9:24.
  CASGoogle Scholar
• 96. Hetta HF, Al-Kadmy IMS, Khazaal SS et al. Antibiofilm and antivirulence potential of silver nanoparticles against multidrug-resistant Acinetobacter baumannii. Sci. Rep. 2021;11:10751.
  Medline CASGoogle Scholar
• 97. Neethu S, Midhun SJ, Radhakrishnan EK et al. Surface functionalization of central venous catheter with mycofabricated silver nanoparticles and its antibiofilm activity on multidrug resistant Acinetobacter baumannii. Microb. Pathog. 2020;138:103832.
  Medline CASGoogle Scholar
• 98. Shahbazi S, Shivaee A, Nasiri M et al. Zinc oxide nanoparticles impact the expression of the genes involved in toxin–antitoxin systems in multidrug-resistant Acinetobacter baumannii. J. Basic Microbiol. 2023;63:1007–1015. •• Showed that the ZnO-nanoparticles potentially impact the expression of the genes involved in toxin-antitoxin systems of MDR A. baumannii which is useful for target-based strategies toward MDR pathogens for clinical applications.
  MedlineGoogle Scholar
• 99. Khanna C, Vashistt J. Exploring biofilm forming capacity of A. baumannii from different clinical sources and screening copper nanoparticles for antibiofilm activity [Bachelor's Thesis] . India: Jaypee University of Information Technology; 2017.
  Google Scholar
• 100. Cochis A, Azzimonti B, Della Valle C et al. The effect of silver or gallium doped titanium against the multidrug resistant Acinetobacter baumannii. Biomaterials 2016;80:80–95.
  Medline CASGoogle Scholar
• 101. Uroz S, Dessaux Y, Oger P. Quorum sensing and quorum quenching: the yin and yang of bacterial communication. ChemBioChem. 2009;10:205–216.
  Medline CASGoogle Scholar
• 102. Bzdrenga J, Daude D, Remy B et al. Biotechnological applications of quorum quenching enzymes. Chem. Biol. Interact. 2017;267:104–115.
  Medline CASGoogle Scholar
• 103. Zhao X, Yu Z, Ding T. Quorum-sensing regulation of antimicrobial resistance in bacteria. Microorganisms 2020;8:425.
  Medline CASGoogle Scholar
• 104. Junter G-A, Thébault P, Lebrun L. Polysaccharide-based antibiofilm surfaces. Acta Biomater. 2016;30:13–25.
  Medline CASGoogle Scholar
• 105. de Freitas SB, Hartwig DD. Promising targets for immunotherapeutic approaches against Acinetobacter baumannii. Microb. Pathog. 2022;173:105855.
  MedlineGoogle Scholar
• 106. Mayer C, Muras A, Romero M et al. Multiple quorum quenching enzymes are active in the nosocomial pathogen Acinetobacter baumannii ATCC17978. Front. Cell Infect. Microbiol. 2018;8:310.
  MedlineGoogle Scholar
• 107. Krzyżek P. Challenges and limitations of anti-quorum sensing therapies. Front. Microbiol. 2019;10:2473.
  MedlineGoogle Scholar
• 108. Asadi A, Razavi S, Talebi M et al. A review on anti-adhesion therapies of bacterial diseases. Infection 2019;47:13–23.
  MedlineGoogle Scholar
• 109. Liu G, Huang Y, Reis FS et al. Impact of nutritional and environmental factors on inflammation, oxidative stress, and the microbiome 2019. Biomed. Res. Int. Hindawi 2019;2019:5716241.
  MedlineGoogle Scholar
• 110. Huan Y, Kong Q, Mou H et al. Antimicrobial peptides: classification, design, application and research progress in multiple fields. Front. Microbiol. 2020;11:2559.
  Google Scholar
• 111. Kakasis A, Panitsa G. Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review. Int. J. Antimicrob. Agents 2019;53:16–21.
  Medline CASGoogle Scholar
• 112. Luong HX, Ngan HD, Thi Phuong HB et al. Multiple roles of ribosomal antimicrobial peptides in tackling global antimicrobial resistance. R. Soc. Open Sci. 2022;9:211583.
  Medline CASGoogle Scholar
• 113. Lee D-K, Bhunia A, Kotler SA et al. Detergent-type membrane fragmentation by MSI-78, MSI-367, MSI-594, and MSI-843 antimicrobial peptides and inhibition by cholesterol: a solid-state nuclear magnetic resonance study. Biochemistry 2015;54:1897–1907.
  Medline CASGoogle Scholar
• 114. Feng X, Sambanthamoorthy K, Palys T et al. The human antimicrobial peptide LL-37 and its fragments possess both antimicrobial and antibiofilm activities against multidrug-resistant Acinetobacter baumannii. Peptides (NY). 2013;49:131–137.
  Medline CASGoogle Scholar
• 115. Zarei-Mehrvarz E, Fahimirad S, Ghaznavi-Rad E et al. The LL-37 antimicrobial peptide as a treatment for systematic infection of Acinetobacter baumannii in a mouse model. Protein Pept. Lett. 2023;30:44–53. •• In vivo results of the study represented a potential of LL37 in the treatment of systematically infected mouse models, and all infected mice treated with LL37 protein survived without a trace of bacteria in their blood samples.
  Medline CASGoogle Scholar
• 116. Guo Y, Xun M, Han J. A bovine myeloid antimicrobial peptide (BMAP-28) and its analogs kill pan-drug-resistant Acinetobacter baumannii by interacting with outer membrane protein A (OmpA). Medicine 2018;97(42):e12832.
  MedlineGoogle Scholar
• 117. Stansly PG. Polymyxin: a new chemotherapeutic agent. Bull. Johns Hopkins Hosp. 1947;81:43.
  Medline CASGoogle Scholar
• 118. Jung C-J, Liao Y-D, Hsu C-C et al. Identification of potential therapeutic antimicrobial peptides against Acinetobacter baumannii in a mouse model of pneumonia. Sci. Rep. 2021;11:7318.
  Medline CASGoogle Scholar
• 119. Wang J, Yadav V, Smart AL et al. Stability of peptide drugs in the colon. Europ. J. Pharmaceut. Sci. 2015;78:31–36.
  Medline CASGoogle Scholar
• 120. Howard-Jones AR, Iredell JR, Khatami A. Phage therapy in pediatrics: the way forward for difficult-to-treat infections? Expert. Rev. Anti Infect Ther. 2022;20:487–491.
  Medline CASGoogle Scholar
• 121. Li Y, Xiao S, Huang G. Acinetobacter baumannii bacteriophage: progress in isolation, genome sequencing, preclinical research, and clinical application. Curr. Microbiol. 2023;80:199.
  Medline CASGoogle Scholar
• 122. Hibstu Z, Belew H, Akelew Y et al. Phage therapy: a different approach to fight bacterial infections. Biologics 2022;16:173–186.
  Medline CASGoogle Scholar
• 123. Wang J-L, Kuo C-F, Yeh C-M et al. Efficacy of φkm18p phage therapy in a murine model of extensively drug-resistant Acinetobacter baumannii infection. Infect. Drug Resist. 2018;11:2301–2310.
  Medline CASGoogle Scholar
• 124. Jeon J, Park J-H, Yong D. Efficacy of bacteriophage treatment against carbapenem-resistant Acinetobacter baumannii in Galleria mellonella larvae and a mouse model of acute pneumonia. BMC Microbiol. 2019;19:1–14.
  MedlineGoogle Scholar
• 125. Wintachai P, Phaonakrop N, Roytrakul S et al. Enhanced antibacterial effect of a novel Friunavirus phage vWU2001 in combination with colistin against carbapenem-resistant Acinetobacter baumannii. Sci. Rep. 2022;12:2633.
  Medline CASGoogle Scholar
• 126. Rouse MD, Stanbro J, Roman JA et al. Impact of frequent administration of bacteriophage on therapeutic efficacy in an A. baumannii mouse wound infection model. Front. Microbiol. 2020;11:414.
  MedlineGoogle Scholar
• 127. Tsonos J, Vandenheuvel D, Briers Y et al. Hurdles in bacteriophage therapy: deconstructing the parameters. Vet. Microbiol. 2014;171:460–469.
  MedlineGoogle Scholar
• 128. Ghasemi F, Jalal R. Antimicrobial action of zinc oxide nanoparticles in combination with ciprofloxacin and ceftazidime against multidrug-resistant Acinetobacter baumannii. J. Glob. Antimicrob. Resist. 2016;6:118–122.
  Medline CASGoogle Scholar
• 129. Martínez-García KD, Zertuche-Arias T, Bernáldez-Sarabia J et al. Radical scavenging, hemocompatibility, and antibacterial activity against MDR Acinetobacter baumannii in alginate-based aerogels containing lipoic acid-capped silver nanoparticles. ACS Omega 2024;9:2350–2361.
  Medline CASGoogle Scholar
• 130. Shi X, Praphakar RA, Suganya K et al. In vivo approach of simply constructed pyrazinamide conjugated chitosan-g-polycaprolactone micelles for methicillin resistance Staphylococcus aureus. Int. J. Biol. Macromol. 2020;158:636–647.
  Medline CASGoogle Scholar
• 131. Kannan S, Solomon A, Krishnamoorthy G et al. Liposome encapsulated surfactant abetted copper nanoparticles alleviates biofilm mediated virulence in pathogenic Pseudomonas aeruginosa and MRSA. Sci. Rep. 2021;11:1102.
  Medline CASGoogle Scholar
• 132. Muthulakshmi L, Suganya K, Murugan M et al. Antibiofilm efficacy of novel biogenic silver nanoparticles from Terminalia catappa against food-borne Listeria monocytogenes ATCC 15,313 and mechanisms investigation in-vivo and in-vitro. J. King Saud Univ. Sci. 2022;34:102083.
  Google Scholar
• 133. Ivanov AV, Bartosch B, Isaguliants MG. Oxidative stress in infection and consequent disease. Oxid. Med. Cell Longev. Hindawi; 2017;2017:3496043.
  MedlineGoogle Scholar
• 134. McNeilly O, Mann R, Hamidian M et al. Emerging concern for silver nanoparticle resistance in Acinetobacter baumannii and other bacteria. Front. Microbiol. 2021;12:652863.
  MedlineGoogle Scholar
• 135. Aljabali AA, Obeid MA, Bashatwah RM et al. Nanomaterials and their impact on the immune system. Int. J. Mol. Sci. 2023;24:2008.
  Medline CASGoogle Scholar
• 136. Herdiana Y, Wathoni N, Shamsuddin S et al. Scale-up polymeric-based nanoparticles drug delivery systems: development and challenges. OpenNano 2022;7:100048.
  Google Scholar
• 137. Rahman Z, Charoo NA, Akhter S et al. Nanotechnology-based drug products: science and regulatory considerations. Nanoscale Fabrication, Optimization, Scale-Up and Biological Aspects of Pharmaceutical Nanotechnology. Newyork (NY):Elsevier; 2018;16:619–655.
  Google Scholar
• 138. Mat Rahim N, Lee H, Strych U et al. Facing the challenges of multidrug-resistant Acinetobacter baumannii: progress and prospects in the vaccine development. Hum. Vaccin. Immunother. 2021;17:3784–3794.
  MedlineGoogle Scholar
• 139. Garcia-Quintanilla M, R Pulido M, J McConnell M. First steps towards a vaccine against Acinetobacter baumannii. Curr. Pharm. Biotechnol. 2013;14:897–902.
  Medline CASGoogle Scholar
• 140. Ramezanalizadeh F, Rasooli I, Owlia P et al. Vaccination with a combination of planktonic and biofilm virulence factors confers protection against carbapenem-resistant Acinetobacter baumannii strains. Sci. Rep. 2022;12:19909.
  Medline CASGoogle Scholar
• 141. McConnell MJ, Rumbo C, Bou G et al. Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii. Vaccine 2011;29:5705–5710.
  Medline CASGoogle Scholar
• 142. Ramezanalizadeh F, Owlia P, Rasooli I. Type I pili, CsuA/B and FimA induce a protective immune response against Acinetobacter baumannii. Vaccine 2020;38:5436–5446.
  Medline CASGoogle Scholar
• 143. Du X, Xue J, Jiang M et al. A multiepitope peptide, rOmp22, encapsulated in chitosan-PLGA nanoparticles as a candidate vaccine against Acinetobacter baumannii infection. Int. J. Nanomed. 2021;16:1819–1836.
  MedlineGoogle Scholar
• 144. Mehdinejadiani K, Hashemi A, Bandehpour M et al. Evaluationof the new outer membrane protein a epitope-based vaccines for mice model of Acinetobacter baumannii associated pneumonia and sepsis infection. Iran J. Allergy Asthma Immunol. 2021;20:537–549.
  MedlineGoogle Scholar
• 145. Yu NY, Wagner JR, Laird MR et al. PSORTb 3.0: improved protein subcellular localization prediction with refined localization subcategories and predictive capabilities for all prokaryotes. Bioinformatics 2010;26:1608–1615.
  Medline CASGoogle Scholar
• 146. Bhasin M, Garg A, Raghava GPS. PSLpred: prediction of subcellular localization of bacterial proteins. Bioinformatics 2005;21:2522–2524.
  Medline CASGoogle Scholar
• 147. Yu C, Lin C, Hwang J. Predicting subcellular localization of proteins for Gram-negative bacteria by support vector machines based on n-peptide compositions. Protein Sci. 2004;13:1402–1406.
  Medline CASGoogle Scholar
• 148. Shen H-B, Chou K-C. Gneg-mPLoc: a top-down strategy to enhance the quality of predicting subcellular localization of Gram-negative bacterial proteins. J. Theor. Biol. 2010;264:326–333.
  Medline CASGoogle Scholar
• 149. Almagro Armenteros JJ, Tsirigos KD, Sønderby CK et al. SignalP 5.0 improves signal peptide predictions using deep neural networks. Nat. Biotechnol. 2019;37:420–423.
  MedlineGoogle Scholar
• 150. Singh H, Raghava GPS. ProPred: prediction of HLA-DR binding sites. Bioinformatics 2001;17:1236–1237.
  Medline CASGoogle Scholar
• 151. Saha S, Raghava GPS. Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Protein. Struct. Funct. Bioinform. 2006;65:40–48.
  Medline CASGoogle Scholar
• 152. Ponomarenko J, Bui H-H, Li W et al. ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinform. 2008;9:1–8.
  MedlineGoogle Scholar
• 153. Haste Andersen P, Nielsen M, Lund OLE. Prediction of residues in discontinuous B-cell epitopes using protein 3D structures. Protein Sci. 2006;15:2558–2567.
  MedlineGoogle Scholar
• 154. Paul S, Sidney J, Sette A et al. TepiTool: a pipeline for computational prediction of T cell epitope candidates. Curr. Protoc. Immunol. 2016;114:18–19.
  Google Scholar
• 155. Magnan CN, Zeller M, Kayala MA et al. High-throughput prediction of protein antigenicity using protein microarray data. Bioinformatics 2010;26:2936–2943.
  Medline CASGoogle Scholar
• 156. He Y, Xiang Z, Mobley HLT. Vaxign: the first web-based vaccine design program for reverse vaccinology and applications for vaccine development. Biomed. Res. Int. 2010;2010:297505.
  Google Scholar
• 157. Walker JM. The Proteomics Protocols Handbook. New Jersey(NJ): Springer; 2005.
  Google Scholar
• 158. Sharma N, Patiyal S, Dhall A et al. AlgPred 2.0: an improved method for predicting allergenic proteins and mapping of IgE epitopes. Brief Bioinform. 2021;22:bbaa294.
  MedlineGoogle Scholar
• 159. Gupta S, Kapoor P, Chaudhary K et al. In silico approach for predicting toxicity of peptides and proteins. PLOS ONE 2013;8:e73957.
  Medline CASGoogle Scholar
• 160. Waterhouse A, Bertoni M, Bienert S et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;46:W296–W303.
  Medline CASGoogle Scholar
• 161. Dominguez C, Boelens R, Bonvin AMJJ. HADDOCK: a protein– protein docking approach based on biochemical or biophysical information. J. Am. Chem. Soc. 2003;125:1731–1737.
  Medline CASGoogle Scholar
• 162. Abraham MJ, Murtola T, Schulz R et al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 2015;1:19–25.
  Google Scholar
• 163. Yang N, Jin X, Zhu C et al. Subunit vaccines for Acinetobacter baumannii. Front. Immunol. 2023;13:1088130.
  MedlineGoogle Scholar
• 164. Ma C, McClean S. Mapping global prevalence of Acinetobacter baumannii and recent vaccine development to tackle it. Vaccines (Basel) 2021;9:570.
  MedlineGoogle Scholar
• 165. Piri-Gharaghie T, Doosti A, Mirzaei SA. Novel adjuvant nano-vaccine induced immune response against Acinetobacter baumannii. AMB Express. 2023;13:1–16.
  MedlineGoogle Scholar
• 166. Hosseinnezhad-Lazarjani E, Doosti A, Sharifzadeh A. Novel csuC-DNA nanovaccine based on chitosan candidate vaccine against infection with Acinetobacter baumannii. Vaccine 2023;41:2170–2183.
  Medline CASGoogle Scholar
• 167. Dey J, Mahapatra SR, Singh PK et al. Designing of multi-epitope peptide vaccine against Acinetobacter baumannii through combined immunoinformatics and protein interaction–based approaches. Immunol. Res. 2023;71(4):639–662.
  Medline CASGoogle Scholar
• 168. Wang SH, Sheng W-H, Chang Y-Y et al. Healthcare-associated outbreak due to pan-drug resistant Acinetobacter baumannii in a surgical intensive care unit. J. Hosp. Infect. 2003;53:97–102.
  Medline CASGoogle Scholar
• 169. Otter JA, Yezli S, French GL. The role played by contaminated surfaces in the transmission of nosocomial pathogens. Infect. Control Hosp. Epidemiol. 2011;32:687–699.
  MedlineGoogle Scholar
• 170. Texidó R, Cabanach P, Kaplan R et al. Bacteriophobic zwitterionic/dopamine coatings for medical elastomers. Adv. Mater. Interfaces 2022;9:2201152.
  CASGoogle Scholar
• 171. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin. Infect. Dis. 2003;36:1111–1118.
  Medline CASGoogle Scholar
• 172. Di Venanzio G, Flores-Mireles AL, Calix JJ et al. Urinary tract colonization is enhanced by a plasmid that regulates uropathogenic Acinetobacter baumannii chromosomal genes. Nat. Commun. 2019;10:2763.
  MedlineGoogle Scholar
• 173. Choe H, Tatro JM, Hausman BS et al. Staphylococcus aureus and Acinetobacter baumannii inhibit osseointegration of orthopedic implants. Infect. Immun. 2022;90:e00669–21.
  Medline CASGoogle Scholar
• 174. Duszynska W, Rosenthal VD, Szczesny A et al. Device associated–health care associated infections monitoring, prevention and cost assessment at intensive care unit of University Hospital in Poland (2015–2017). BMC Infect. Dis. 2020;20:761.
  Medline CASGoogle Scholar
• 175. Sharifipour E, Shams S, Esmkhani M et al. Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU. BMC Infect. Dis. 2020;20:1–7.
  Google Scholar
• 176. Tacconelli E, Cataldo MA, Dancer SJ et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin. Microbiol. Infect. 2014;20:1–55.
  MedlineGoogle Scholar
• 177. Iyer R, Moussa SH, Durand-Reville TF et al. Acinetobacter baumannii OmpA is a selective antibiotic permeant porin. ACS Infect. Dis. 2017;4:373–381.
  MedlineGoogle Scholar
• 178. Zeighami H, Valadkhani F, Shapouri R et al. Virulence characteristics of multidrug resistant biofilm forming Acinetobacter baumannii isolated from intensive care unit patients. BMC Infect. Dis. 2019;19:1–9. • Reported the biofilm formation among clinical isolates of A. baumannii and the genes related to biofilm formation, they found that csuE was the most prevalent gene present in biofilm-forming A. baumannii.
  Medline CASGoogle Scholar
• 179. Badmasti F, Siadat SD, Bouzari S et al. Molecular detection of genes related to biofilm formation in multidrug-resistant Acinetobacter baumannii isolated from clinical settings. J. Med. Microbiol. 2015;64:559–564.
  Medline CASGoogle Scholar
• 180. Russo TA, Luke NR, Beanan JM et al. The K1 capsular polysaccharide of Acinetobacter baumannii strain 307–0294 is a major virulence factor. Infect. Immun. 2010;78:3993–4000.
  Medline CASGoogle Scholar
• 181. Chen X, Meng X, Gao Q et al. Meropenem selection induced overproduction of the intrinsic carbapenemase as well as phenotype divergence in Acinetobacter baumannii. Int. J. Antimicrob. Agents 2017;50:419–426.
  Medline CASGoogle Scholar
• 182. Wang-Lin SX, Olson R, Beanan JM et al. The capsular polysaccharide of Acinetobacter baumannii is an obstacle for therapeutic passive immunization strategies. Infect. Immun. 2017;85:10–1128.
  Google Scholar
• 183. Shah P, Swiatlo E. A multifaceted role for polyamines in bacterial pathogens. Mol. Microbiol. 2008;68:4–16.
  Medline CASGoogle Scholar
• 184. Igarashi K, Kashiwagi K. Modulation of cellular function by polyamines. Int. J. Biochem. Cell Biol. 2010;42:39–51.
  Medline CASGoogle Scholar
• 185. Huang G, Shen X, Gong Y et al. Antibacterial properties of Acinetobacter baumannii phage Abp1 endolysin (PlyAB1). BMC Infect. Dis. 2014;14:1–8.
  MedlineGoogle Scholar
• 186. Wu M, Hu K, Xie Y et al. A novel phage PD-6A3, and its endolysin Ply6A3, with extended lytic activity against Acinetobacter baumannii. Front. Microbiol. 2019;9:3302.
  MedlineGoogle Scholar
• 187. Lood R, Winer BY, Pelzek AJ et al. Novel phage lysin capable of killing the multidrug-resistant Gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model. Antimicrob. Agents Chemother. 2015;59:1983–1991.
  Medline CASGoogle Scholar
• 188. Hyman P, Abedon ST. Bacteriophage host range and bacterial resistance. Adv. Appl. Microbiol. 2010;70:217–248.
  Medline CASGoogle Scholar
• 189. Fauconnier A. Phage therapy regulation: from night to dawn. Viruses 2019;11:352.
  MedlineGoogle Scholar
• 190. Almotairy ARZ, Amer AM, El-Kady H et al. Nanostructured γ-Al2O3 synthesis using an arc discharge method and its application as an antibacterial agent against XDR bacteria. Inorganics (Basel) 2023;11:42.
  CASGoogle Scholar
• 191. Niakan S, Niakan M, Hesaraki S et al. Comparison of the antibacterial effects of nanosilver with 18 antibiotics on multidrug resistance clinical isolates of Acinetobacter baumannii. Jundishapur J. Microbiol. 2013;6(5):e8341.
  Google Scholar
• 192. Gui S, Li X, Feng M et al. A fresh pH-responsive imipenem-loaded nanocarrier against Acinetobacter baumannii with a synergetic effect. Front. Bioeng. Biotechnol. 2023;11:1166790.
  MedlineGoogle Scholar
• 193. Natsheh IY, Elkhader MT, Al-Bakheit AA et al. Inhibition of Acinetobacter baumannii biofilm formation using different treatments of silica nanoparticles. Antibiotics 2023;12:1365.
  CASGoogle Scholar
• 194. Mukherjee A, Bose S, Shaoo A et al. Nanotechnology based therapeutic approaches: an advanced strategy to target the biofilm of ESKAPE pathogens. Mater Adv. 2023;4:2544–2572.
  CASGoogle Scholar
• 195. Daisy ERAC, Rajan M, Suganya K et al. Fungal Keratitis infected eye treatment with antibiotic-loaded zinc ions tagged polyvinyl acetate phthalate-g-polypyrrole drug carrier. J. Saudi Chem. Soc. 2021;25:101347.
  Google Scholar
• 196. Murugesan G, Latha N, Suganya K et al. Stimulus-responsive zinc oxide-functionalized macromolecular humic acid nanocarrier for enhancement of antibacterial activity of ciprofloxacin hydrochloride. Int. J. Biol. Macromol. 2018;114:1109–1116.
  Medline CASGoogle Scholar
• 197. Wei R, Yang X, Liu H et al. Synthetic pseudaminic-acid-based antibacterial vaccine confers effective protection against Acinetobacter baumannii infection. ACS Cent Sci. 2021;7:1535–1542.
  Medline CASGoogle Scholar
• 198. Uppuluri P, Lin L, Alqarihi A et al. The Hyr1 protein from the fungus Candida albicans is a cross kingdom immunotherapeutic target for Acinetobacter bacterial infection. PLoS Pathog. 2018;14:e1007056.
  MedlineGoogle Scholar
• 199. Ahmad TA, Tawfik DM, Sheweita SA et al. Development of immunization trials against Acinetobacter baumannii. Trials Vaccinol. 2016;5:53–60.
  Google Scholar
• 200. Kennedy DA, Read AF. Why does drug resistance readily evolve but vaccine resistance does not? Proc. Royal Soc. B: Biolog. Sci. 2017;284:20162562.
  Google Scholar
• 201. Ud-Din M, Albutti A, Ullah A et al. Vaccinomics to design a multi-epitopes vaccine for Acinetobacter baumannii. Int. J. Environ. Res. Public Health 2022;19:5568.
  Medline CASGoogle Scholar
• 202. Bertin ML, Vinski J, Schmitt S et al. Outbreak of methicillin-resistant Staphylococcus aureus colonization and infection in a neonatal intensive care unit epidemiologically linked to a healthcare worker with chronic otitis. Infect. Control Hosp. Epidemiol. 2006;27:581–585.
  MedlineGoogle Scholar
• 203. Bryant KA, Humbaugh K, Brothers K et al. Measures to control an outbreak of pertussis in a neonatal intermediate care nursery after exposure to a healthcare worker. Infect. Control Hosp. Epidemiol. 2006;27:541–545.
  MedlineGoogle Scholar
• 204. Shen N, Cheng E, Whitley JW et al. Photograftable zwitterionic coatings prevent Staphylococcus aureus and Staphylococcus epidermidis adhesion to PDMS surfaces. ACS Appl. Bio. Mater. 2021;4:1283–1293.
  Medline CASGoogle Scholar
• 205. Ghavamian S, Hay ID, Habibi R et al. Three-dimensional micropatterning deters early bacterial adherence and can eliminate colonization. ACS Appl. Mater. Interf. 2021;13:23339–23351.
  Medline CASGoogle Scholar
• 206. Ozkan E, Mondal A, Douglass M et al. Bioinspired ultra-low fouling coatings on medical devices to prevent device-associated infections and thrombosis. J. Colloid. Interf. Sci. 2022;608:1015–1024.
  Medline CASGoogle Scholar
• 207. Francone A, Merino S, Retolaza A et al. Impact of surface topography on the bacterial attachment to micro-and nano-patterned polymer films. Surf. Interf. 2021;27:101494.
  Medline CASGoogle Scholar